134 related articles for article (PubMed ID: 38305604)
21. Identification of shared gene signatures in major depressive disorder and triple-negative breast cancer.
Xie H; Ding C; Li Q; Sheng W; Xu J; Feng R; Cheng H
BMC Psychiatry; 2024 May; 24(1):369. PubMed ID: 38755543
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological Features of Triple-Negative Breast Cancer Epigenetic Subtypes.
DiNome ML; Orozco JIJ; Matsuba C; Manughian-Peter AO; Ensenyat-Mendez M; Chang SC; Jalas JR; Salomon MP; Marzese DM
Ann Surg Oncol; 2019 Oct; 26(10):3344-3353. PubMed ID: 31342401
[TBL] [Abstract][Full Text] [Related]
23. Identification of key genes as potential biomarkers for triple‑negative breast cancer using integrating genomics analysis.
Zhong G; Lou W; Shen Q; Yu K; Zheng Y
Mol Med Rep; 2020 Feb; 21(2):557-566. PubMed ID: 31974598
[TBL] [Abstract][Full Text] [Related]
24. Epigenomic Profiling Advises Therapeutic Potential of Leukotriene Receptor Inhibitors for a Subset of Triple-Negative Breast Tumors.
Kalinkin AI; Sigin VO; Kuznetsova EB; Ignatova EO; Vinogradov II; Vinogradov MI; Vinogradov IY; Zaletaev DV; Nemtsova MV; Kutsev SI; Tanas AS; Strelnikov VV
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139172
[TBL] [Abstract][Full Text] [Related]
25. Identification of differentially expressed genes between triple and non-triple-negative breast cancer using bioinformatics analysis.
Zhai Q; Li H; Sun L; Yuan Y; Wang X
Breast Cancer; 2019 Nov; 26(6):784-791. PubMed ID: 31197620
[TBL] [Abstract][Full Text] [Related]
26. Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration.
Terkelsen T; Russo F; Gromov P; Haakensen VD; Brunak S; Gromova I; Krogh A; Papaleo E
Breast Cancer Res; 2020 Jun; 22(1):73. PubMed ID: 32605588
[TBL] [Abstract][Full Text] [Related]
27. KEGG-expressed genes and pathways in triple negative breast cancer: Protocol for a systematic review and data mining.
Chen J; Liu C; Cen J; Liang T; Xue J; Zeng H; Zhang Z; Xu G; Yu C; Lu Z; Wang Z; Jiang J; Zhan X; Zeng J
Medicine (Baltimore); 2020 May; 99(18):e19986. PubMed ID: 32358373
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of CCNE1 confers a poorer prognosis in triple-negative breast cancer identified by bioinformatic analysis.
Yuan Q; Zheng L; Liao Y; Wu G
World J Surg Oncol; 2021 Mar; 19(1):86. PubMed ID: 33757543
[TBL] [Abstract][Full Text] [Related]
29. Molecular Features of Triple Negative Breast Cancer: Microarray Evidence and Further Integrated Analysis.
He J; Yang J; Chen W; Wu H; Yuan Z; Wang K; Li G; Sun J; Yu L
PLoS One; 2015; 10(6):e0129842. PubMed ID: 26103053
[TBL] [Abstract][Full Text] [Related]
30. A novel fatty-acid metabolism-based classification for triple negative breast cancer.
Yang X; Tang W; He Y; An H; Wang J
Aging (Albany NY); 2023 Feb; 15(4):1177-1198. PubMed ID: 36880837
[TBL] [Abstract][Full Text] [Related]
31. Downregulation of the enhancer of zeste homolog 1 transcriptional factor predicts poor prognosis of triple-negative breast cancer patients.
Peng W; Tang W; Li JD; He RQ; Luo JY; Chen ZX; Zeng JH; Hu XH; Zhong JC; Li Y; Ma FC; Xie TY; Huang SN; Ge LY
PeerJ; 2022; 10():e13708. PubMed ID: 35846880
[TBL] [Abstract][Full Text] [Related]
32. Retrospective study of transcriptomic profiling identifies Thai triple-negative breast cancer patients who may benefit from immune checkpoint and PARP inhibitors.
Suntiparpluacha M; Chanthercrob J; Sa-Nguanraksa D; Sitthikornpaiboon J; Chaiboonchoe A; Kueanjinda P; Jinawath N; Sampattavanich S
PeerJ; 2023; 11():e15350. PubMed ID: 37334114
[TBL] [Abstract][Full Text] [Related]
33. Risk stratification of triple-negative breast cancer with core gene signatures associated with chemoresponse and prognosis.
Kim EK; Park AK; Ko E; Park WY; Lee KM; Noh DY; Han W
Breast Cancer Res Treat; 2019 Nov; 178(1):185-197. PubMed ID: 31342312
[TBL] [Abstract][Full Text] [Related]
34. ABCC9, NKAPL, and TMEM132C are potential diagnostic and prognostic markers in triple-negative breast cancer.
Zhang X; Kang X; Jin L; Bai J; Zhang H; Liu W; Wang Z
Cell Biol Int; 2020 Oct; 44(10):2002-2010. PubMed ID: 32544280
[TBL] [Abstract][Full Text] [Related]
35. Gene regulatory pattern analysis reveals essential role of core transcriptional factors' activation in triple-negative breast cancer.
Min L; Zhang C; Qu L; Huang J; Jiang L; Liu J; Pinello L; Yuan GC; Shou C
Oncotarget; 2017 Mar; 8(13):21938-21953. PubMed ID: 28423538
[TBL] [Abstract][Full Text] [Related]
36. Gene and lncRNA co-expression network analysis reveals novel ceRNA network for triple-negative breast cancer.
Le K; Guo H; Zhang Q; Huang X; Xu M; Huang Z; Yi P
Sci Rep; 2019 Oct; 9(1):15122. PubMed ID: 31641220
[TBL] [Abstract][Full Text] [Related]
37. Integrative transcriptome analysis of triple negative breast cancer profiles for identification of druggable targets.
Arumugam P; Ramesh V; Sampathkumar B; Perumalsamy H; Balusamy SR; Suganya K; Balraj S; Nachimuthu SK; Sundaravadivelu S
J Biomol Struct Dyn; 2023; 41(21):12106-12119. PubMed ID: 36617953
[TBL] [Abstract][Full Text] [Related]
38. Identification of hub genes and diagnostic efficacy for triple-negative breast cancer through WGCNA and Mendelian randomization.
Lin Y; Wang S; Yang Q
Discov Oncol; 2024 Apr; 15(1):117. PubMed ID: 38609711
[TBL] [Abstract][Full Text] [Related]
39. Classification of triple-negative breast cancers based on Immunogenomic profiling.
He Y; Jiang Z; Chen C; Wang X
J Exp Clin Cancer Res; 2018 Dec; 37(1):327. PubMed ID: 30594216
[TBL] [Abstract][Full Text] [Related]
40. A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer.
Zhang J; Zhang M; Tian Q; Yang J
Clin Exp Med; 2023 Nov; 23(7):3867-3881. PubMed ID: 37219794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
